Irene C. Waizenegger - Boehringer Ingelheim RCV

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 47 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyová,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumüller

crossref（2025）

Cited0Views0Bibtex

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyova,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumueller

CANCER DISCOVERYno. 1 (2025): 119-138

Cited0Views0WOSBibtex

SOS1 Inhibitor Treatment Improves Response to Venetoclax in Acute Myeloid Leukemia

Kaja Kostyrko,Melanie Hinkel,Matthew G. Rees,Melissa M. Ronan,Jennifer A. Roth,Daniel Gerlach,Irene Waizenegger

Cancer Researchno. 6_Supplement (2024): 6564-6564

Cited0Views0Bibtex

Therapeutic Potential of SOS1 and KRAS Inhibitors in Malignant Peripheral Nerve Sheath Tumors

Ozlem Yuce Petronczki,Laura Pisarsky, Petra Lujza Szabo,Julia Brunmair, Antonia Geyer,Norbert Kraut,Darryl McConnell,Irene Waizenegger

Cancer Researchno. 6_Supplement (2024): 4564-4564

Cited0Views0Bibtex

Co-targeting SOS1 Enhances the Antitumor Effects of KRASG12C Inhibitors by Addressing Intrinsic and Acquired Resistance

NATURE CANCERno. 9 (2024)

Cited1Views0WOSNATUREBibtex

Supplementary Tables S5 and S6 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation

Irene C. Waizenegger,Anke Baum,Steffen Steurer,Heinz Stadtmüller,Gerd Bader,Otmar Schaaf,Pilar Garin-Chesa,Andreas Schlattl,Norbert Schweifer,Christian Haslinger,Florian Colbatzky,Sien Mousa,Arno Kalkuhl,Norbert Kraut,Günther R. Adolf

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn